Pediatrix Medical Group, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a net revenue of $492.9 million for the three months ended September 30, 2025, a decrease of 3.6% from $511.2 million in the same period of 2024. For the nine months ended September 30, 2025, net revenue totaled $1.42 billion, down 6.0% from $1.51 billion in the prior year. The decline in revenue was primarily attributed to non-same unit activity, particularly from practice dispositions, although same-unit revenue increased by 8.0% during the quarter, driven by improved collection activity and increased patient acuity in neonatology.
The company reported a significant increase in profitability, with net income reaching $71.7 million for the third quarter of 2025, compared to $19.4 million in the same quarter of 2024. For the nine-month period, net income was $131.7 million, a turnaround from a net loss of $129.5 million in the prior year. The operating income for the third quarter increased by 101.2% to $68.1 million, resulting in an operating margin of 13.8%, up from 6.6% in the same quarter of 2024. This improvement was largely due to favorable same-unit results and the impact of practice disposition activities.
In terms of strategic developments, Pediatrix completed the acquisition of several neonatology, maternal-fetal medicine, and OB hospitalist practices on September 1, 2025, for a total consideration of $19.2 million. This acquisition is expected to enhance the company's national network of physician practices in women's and children's services. Additionally, the company recognized a net gain of $28.8 million on an investment in a divested business during the third quarter, further contributing to its financial performance.
Operationally, Pediatrix reported a decrease in practice salaries and benefits, which fell by 8.9% to $332.3 million for the third quarter, reflecting the impact of practice dispositions. The company also noted a reduction in accounts payable and accrued expenses, which decreased to $352.2 million from $398.7 million at the end of 2024. As of September 30, 2025, Pediatrix had cash and cash equivalents of $340.1 million, an increase from $229.9 million at the end of 2024, indicating improved liquidity.
Looking ahead, Pediatrix anticipates that its operational cash flow, combined with available credit, will be sufficient to meet its working capital needs and fund future acquisitions and capital expenditures. The company remains focused on its transformation initiatives, particularly its shift back to a hospital-based and maternal-fetal medicine-focused organization, following the exit from most of its affiliated office-based practices. The management's outlook suggests a commitment to enhancing operational efficiency and profitability in the evolving healthcare landscape.
About Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. provides physician services in neonatal, maternal-fetal, and pediatric subspecialties. Its network includes neonatologists, obstetricians, pediatric intensivists, and surgeons serving hospitals across the U.S. through hospital-based units and outpatient clinics. The company focuses on improving patient outcomes via clinical research, quality initiatives, and advanced health IT, supporting hospital partners, physicians, and payors in delivering cost-effective, high-quality care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.